Stroke patients show higher recovery in MultiStem therapy

February 24, 2016

Data presented by the biotech company Athersys indicate that stroke patients treated by an adult stem cell therapy called MultiStem did significantly better than others who received a placebo one year after treatment. The results are from a Phase 2 study involving clinical sites in the United States and the United Kingdom, including University Hospitals Case Medical Center. The study examined the safety and effectiveness of the new therapy developed for the treatment of ischemic stroke. The data were presented Feb. 17 at the 2016 International Stroke Conference in Los Angeles.

Of the 65 treated with MultiStem, 23.1 percent achieved a complete or near full recovery from their after one year. Only 8.2 percent of the 61 placebo patients achieved that level of recovery. Patients who received the cell therapy within 36 hours after the onset of stroke did even better, with 29 percent of those 31 patients achieving an excellent outcome.

Cathy Sila, MD, Director of the Comprehensive Stroke Center at UH Case Medical Center, and Professor of Neurology at Case Western Reserve University, was the principal investigator of the study at UH Case Medical Center.

"These results are very promising and this therapy would be an important adjunct to acute to reduce the amount of brain injury from which patients need to recover," said Dr. Sila. "But the results are still preliminary and need to be reproduced."

Since MultiStem therapy seems to be effective when given at 24 to 36 hours after the stroke, it means many more would be eligible for treatment, she said.

"Current therapy for stroke is unfortunately very limited. There is only one drug, tPA, that is FDA approved for , and tPA needs to be administered within hours of onset of a stroke," said Dr. Sila. "Despite public education and the development of , only about 7 percent of all patients nationwide receive tPA therapy and less than 2 percent undergo catheter-based clot removal . New treatments are needed to reverse the effects of a stroke and promote recovery from stroke, and they need to be effective in a wider time window to help more patients."

Ischemic stroke is caused by blockage in an artery in or to the brain, that impedes blood flow, and that can result in serious disability or even death.

MultiStem is a proprietary medication made by the Cleveland-based biotech company Athersys. The medication comes from a patented class of early adult stem cells called Multipotent Adult Progenitor Cells or MAPCs that are obtained from bone marrow. Hundreds of thousands to millions of doses can be made from the bone marrow cells of one donor. The cells do not come from the patient, so can be made in advance, stored in the hospital and be used off the shelf.

MultiStem cells appear to reduce the local inflammatory response and protect neurons in the brain, while modulating the body's general immune response and inflammation which leads to additional damage to the brain in the days immediately following the stroke. This is an entirely new concept for how cell therapies may provide benefit following central nervous system injury.

The Phase 2 study was double-blind (meaning both the patient and the doctors evaluating the patients didn't know which arm of the study the patient was in), randomized, and placebo-controlled. The study was funded by Athersys.

Explore further: Imaging, not time, may determine who is right for stroke clot removal

Related Stories

Imaging, not time, may determine who is right for stroke clot removal

February 17, 2016
Brain imaging may accurately identify patients likely to benefit from stroke clot removal instead of relying on the time since symptoms began as an indicator of treatment eligibility, according to research presented at the ...

Quicker clot removal may lead to better outcomes

February 17, 2016
The faster a blood clot causing a stroke is removed, the less disability a patient may have, according to research presented at the American Stroke Association's International Stroke Conference 2016.

Endovascular treatment may preserve mental capacity after stroke

February 17, 2016
In addition to improving survival and reducing disability, mechanically removing the clot causing an ischemic stroke leads to better cognitive functioning, according to research presented at the American Stroke Association's ...

University of Kentucky offers stroke stem cell trial

January 13, 2012
The University of Kentucky will be the first site in the state and one of a select few in the entire country participating in the first stages of a groundbreaking study to investigate the effects of MultiStem, a human adult ...

Clot removal may save money and limit disability

February 17, 2016
Adding mechanical clot removal to clot-busting drugs could lower stroke survivors medical bills, decrease government healthcare as well as non-healthcare related costs, and increase the likelihood of the patient returning ...

Endovascular intervention compared to standard treatment for stroke

November 3, 2015
In a meta-analysis of randomized clinical trials for the treatment of acute ischemic stroke, an endovascular intervention (such as use of a very small catheter to remove a blood clot) compared to standard medical care (administration ...

Recommended for you

High blood pressure linked to common heart valve disorder

October 17, 2017
For the first time, a strong link has been established between high blood pressure and the most common heart valve disorder in high-income countries, by new research from The George Institute for Global Health at the University ...

Saving hearts after heart attacks: Overexpression of a gene enhances repair of dead muscle

October 17, 2017
University of Alabama at Birmingham biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch. The key was overexpressing ...

Blood cancer gene could be key to preventing heart failure

October 16, 2017
A new study, published today in Circulation, shows that the gene Runx1 increases in damaged heart muscle after a heart attack. An international collaboration led by researchers from the University of Glasgow, found that mice ...

Mitochondrial DNA could predict risk for sudden cardiac death, heart disease

October 11, 2017
Johns Hopkins researchers report that the level, or "copy number," of mitochondrial DNA—genetic information stored not in a cell's nucleus but in the body's energy-creating mitochondria—is a novel and distinct biomarker ...

Tai chi holds promise as cardiac rehab exercise

October 11, 2017
The slow and gentle movements of Tai Chi hold promise as an alternative exercise option for patients who decline traditional cardiac rehabilitation, according to preliminary research in Journal of the American Heart Association, ...

Meeting an unmet need: A surgical implant that grows with a child

October 10, 2017
Medical implants can save lives by correcting structural defects in the heart and other organs. But until now, the use of medical implants in children has been complicated by the fact that fixed-size implants cannot expand ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.